EUVIMEDEUVIMED entdecken
Crossref

US Spending on High-Revenue Rare Disease Drugs in 2022

Helen Mooney, Aaron S Kesselheim, Benjamin N Rome

The American Journal of Managed Care · 2025

DOI: 10.37765/ajmc.2025.89823 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of Managed Care, 2025. Verfasst von Helen Mooney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont St, Ste 3030, Boston, MA 0…. Hauptthemen laut MEDLINE: Rare Diseases, Orphan Drug Production, Prescription Drugs, Health Expenditures.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesOrphan Drug ProductionPrescription DrugsHealth ExpendituresUnited StatesHumansCross-Sectional StudiesMedicaidMedicareDrug Costs

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120. Email: brome@bwh.harvard.edu.

Zitieren

APA

Mooney, H., Kesselheim, A. S., & Rome, B. N. (2025). US Spending on High-Revenue Rare Disease Drugs in 2022. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2025.89823

Vancouver

Mooney H, Kesselheim AS, Rome BN. US Spending on High-Revenue Rare Disease Drugs in 2022. The American Journal of Managed Care. 2025. doi:10.37765/ajmc.2025.89823

BibTeX
@article{Mooney2025,
  author = {Mooney, Helen and Kesselheim, Aaron S and Rome, Benjamin N},
  title = {US Spending on High-Revenue Rare Disease Drugs in 2022},
  journal = {The American Journal of Managed Care},
  year = {2025},
  doi = {10.37765/ajmc.2025.89823}
}
Kostenlos starten →